Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression.

Adenovirus-based gene therapy offers a unique opportunity to target gene expression to the liver by systemic delivery. However, systemic administration of a first generation adenoviral construct elicits an inflammatory response leading to TNF-alpha-dependent liver injury. The aim of this study was to evaluate whether the systemic administration of recombinant adenovirus exacerbates a subsequent TNF-alpha-dependent liver injury induced by D-galactosamine and lipopolysaccharide. Surprisingly, low-dose adenovirus administration (10(5) particles) protects, while high-dose adenovirus (10(10) particles) is associated with an exaggerated hepatic inflammatory response from a subsequent D-galactosamine and lipopolysaccharide challenge. This exacerbation is TNF-alpha dependent, since treatment with a TNF inhibitor fully protects against the liver injury. Moreover, intravenous administration of an adenoviral construct expressing the anti-inflammatory protein interleukin-10 reduces TNF-alpha appearance and attenuates the increased hepatocyte injury. Taken together, this report demonstrates potential additive effects of TNF-alpha responses induced by adenovirus and other inflammatory signals, and suggests that the response can be mitigated by relative adenovirus particle dose or by inhibitors, such as TNF-binding protein or interleukin 10.

[1]  L. Moldawer,et al.  Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Komatsu,et al.  Immune responses against replication-deficient adenovirus inhibit ovalbumin-specific allergic reactions in mice. , 2000, Human gene therapy.

[3]  P. Roberts,et al.  Alpha/Beta Interferons Potentiate Virus-Induced Apoptosis through Activation of the FADD/Caspase-8 Death Signaling Pathway , 2000, Journal of Virology.

[4]  L. Moldawer,et al.  TNF-α Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung1 , 2000, The Journal of Immunology.

[5]  N. Lemoine,et al.  A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. , 1999, Human gene therapy.

[6]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[7]  J. Dhainaut,et al.  LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. , 1999, American journal of respiratory and critical care medicine.

[8]  L. Moldawer,et al.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.

[9]  D. Brenner,et al.  NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. , 1998, The Journal of clinical investigation.

[10]  M. Kay,et al.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.

[11]  R. Crystal,et al.  Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors , 1997 .

[12]  M. Lusky,et al.  Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. , 1997, Immunology letters.

[13]  M. Jordana,et al.  Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia , 1997, Gene Therapy.

[14]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[15]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[16]  M. Kay,et al.  Adenovirus-mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. , 1996, Human gene therapy.

[17]  J. Wang,et al.  Role of lipopolysaccharide and tumor necrosis factor-alpha in induction of hepatocyte necrosis. , 1995, The American journal of physiology.

[18]  F. Graham,et al.  Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.

[19]  Hanns Lochmüller,et al.  The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. , 1995, Gene therapy.

[20]  M. Leist,et al.  Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. , 1995, Journal of immunology.

[21]  H. Shepard,et al.  Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.

[22]  C. Biron.  Cytokines in the generation of immune responses to, and resolution of, virus infection. , 1994, Current opinion in immunology.

[23]  C. Galanos,et al.  Mechanisms of endotoxin shock and endotoxin hypersensitivity. , 1993, Immunobiology.

[24]  H. Langstein,et al.  Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats , 1991, Infection and immunity.

[25]  H. Langstein,et al.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. , 1991, The Journal of clinical investigation.

[26]  R. Chanock,et al.  A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Chanock,et al.  Role of early genes in pathogenesis of adenovirus pneumonia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[29]  L. Moldawer,et al.  AREGU May 47/5 , 2000 .